New Clinical AI care suites for Cardiology, Pulmonology, and Neurology; First-in-Class multi-modal predictive and Gen AI platform for research and clinical model development.
ConcertAI’s TeraRecon, the #1 KLAS-ranked advanced visualization and AI Clinical SaaS solution, has announced that European healthcare providers now have access to its cardiology, pulmonology, and neurology suites. In addition, the company initiated new partnerships with several leading CE-marked AI software developers, including Gleamer, Lucida Medical, and Perspectum. TeraRecon now provides a leading unified solution for clinical AI algorithms in Europe across radiology, neurology, oncology, pulmonology, and cardiology.
TeraRecon’s AI Partnerships for the EU market now include:
- GLEAMER brings their groundbreaking BoneView solution, CE marked and FDA-cleared, utilizes AI for bone fracture identification. Meanwhile, ChestView (CE) aids in the detection of pulmonary nodules.
- Lucida Medical AI-machine learning software, Pi™, is designed to help radiologists identify prostate cancer lesions from MRI.
- Perspectum’s LiverMultiscan and MRCP+ provide clinicians with quantitative metrics to assess liver tissue characteristics to aid in the detection of chronic live disease and helps facilitate visualization and quantitative assessment of the biliary tree and pancreatic duct.
Also Read: Curia Appoints Steve Lavezoli as Vice President, Biologics
Another exciting launch at ECR is an integrated multi-modal data AI Software-as-a-Service platform designed for oncology biomedical translational and clinical research, AI model development, multi-modal data management. This first-in-class platform seamlessly integrates Intuition advanced visualization, TeraRecon clinical AI imaging solutions, digital pathology, genomics, and electronic medical record derived clinical data.
“Over the past two years, we have focused on the importance of multi-modal data AI model development, validation, stability monitoring, and deployment for insights, as part of clinical trials, and ultimately, clinical care,” said Jeff Elton, PhD CEO of ConcertAI. “Multi-modal data enable causal inferences and elimination of confounders for interpretations and predictions. Enabling this required rethinking the tools available to biomedical researchers, while leveraging the power of Generative AI. As a ground-up new approach that allows multi-modal data management, AI model development validation, model management, and model release we can bring the power of deep and wide data at scale, our large research network, and latest predictive AI and Gen AI together for the broadest research community use.”
SOURCE: PRNewswire
